ReviewJournal of clinical immunology2014
MMN: from immunological cross-talk to conduction block.
Review in Journal of clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- High Resolution 3-T Magnetic Resonance Tractography Cannot Localise Conduction Block in Multifocal Motor Neuropathy With Conduction Block.Journal of the peripheral nervous system : JPNS · 2026Article
- IgM Anti-Ganglioside Binding and Complement Activation in an iPSC-Derived Motor Neuron Model for Multifocal Motor Neuropathy.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Multifocal Motor Neuropathy: A Narrative Review.Muscle & nerve · 2025Review
- Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.Journal of pharmacy practice · 2022Review
- Application and Research Progress of High Frequency Ultrasound in the Diagnosis of Chronic Inflammatory Neuropathies.Frontiers in neurology · 2022Review
- Article
- Nerve Ultrasound as Helpful Tool in Polyneuropathies.Diagnostics (Basel, Switzerland) · 2021Review
- Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration.Brain : a journal of neurology · 2020Review
- Multifaceted Genes in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia.Frontiers in neuroscience · 2020Review
- Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis.Cell reports · 2019Article
- Conduction Block and Nerve Cross-Sectional Area in Multifocal Motor Neuropathy.Frontiers in neurology · 2019Article
- Immune-mediated neuropathies.Nature reviews. Disease primers · 2018Review
- Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies.Journal of the peripheral nervous system : JPNS · 2018Review
- Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.Nature reviews. Neurology · 2017Review
- Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy.Annals of clinical and translational neurology · 2016Article
- The pathogenesis of multifocal motor neuropathy and an update on current management options.Therapeutic advances in neurological disorders · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multifocal motor neuropathy (MMN) is a rare inflammatory neuropathy characterized by progressive, asymmetric distal limb weakness and conduction block (CB). Clinically MMN is a pure motor neuropathy, which as such can mimic motor neuron disease. GM1-specific IgM antibodies are present in the serum of approximately half of all MMN patients, and are thought to play a key role in the immune pathophysiology. Intravenous immunoglobulin (IVIg) treatment has been shown to be effective in MMN in five randomized placebo-controlled trials. Despite long-term treatment with intravenous immunoglobulin (IVIg), which is efficient in the majority of patients, slowly progressive axonal degeneration and subsequent muscle weakness cannot be fully prevented. In this review, we will discuss the current understanding of the immune pathogenesis underlying MMN and how this may cause CB, available treatment strategies and future therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.